Controversies in the use of second generation antipsychotics as sleep agent

Pharmacological Research

Volumn 79, Issue , 2014, Pages 1-8

  Shah, Chintan ^a   Sharma, Taral R ^a   Kablinger, Anita ^a  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

Author keywords

Pharmacology; Second generation antipsychotics; Sleep

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CLOZAPINE; DIPHENHYDRAMINE; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; GABAPENTIN; HALOPERIDOL; MELATONIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUAZEPAM; QUETIAPINE; RAMELTEON; RISPERIDONE; TAMOXIFEN; TEMAZEPAM; TIAGABINE; TRAZODONE; TRIAZOLAM; TRIMIPRAMINE; UNINDEXED DRUG; VALERIAN; ZALEPLON; ZIPRASIDONE; ZOLPIDEM;

BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COGNITIVE DEFECT; DRUG FATALITY; DRUG MECHANISM; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERGLYCEMIA; INSOMNIA; NEUROCHEMISTRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP; SLEEP DISORDER; SLEEP INDUCTION; SLEEP PATTERN; TARDIVE DYSKINESIA; WAKEFULNESS; WEIGHT GAIN;

PHARMACOLOGY; SECOND GENERATION ANTIPSYCHOTICS; SLEEP;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; HYPNOTICS AND SEDATIVES; OFF-LABEL USE; SLEEP; SLEEP DISORDERS;

EID: 85047689426     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.10.005     Document Type: Review

References (94)

1. D.E. Moul, E.A. Nofzinger, P.A. Pilkonis, P.R. Houck, J.M. Miewald, and D.J. Buysse Symptom reports in severe chronic insomnia Sleep 25 2002 553 563 (Pubitemid 34787381)
2. J. Lu, and M.A. Greco Sleep circuitry and the hypnotic mechanism of GABA-A drugs J Clin Sleep Med 2 2 2006 S19 S26
3. M.E. Carter, L. de Lecea, and A. Adamantidis Functional wiring of hypocretin and LC-NE neurons: implications for arousal Front Behav Neurosci 7 2013 43 10.3389/fnbeh.2013.00043 [eCollection 2013]
4. P.M. Fuller, J.J. Gooley, and C.B. Saper Neurobiology of the sleep-wake cycle: sleep architecture, circadian, regulation, and regulatory feedback J Biol Rhythms 21 2006 482 493 (Pubitemid 44706829)
5. A.H. Hallanger, A.I. Levey, H.G. Lee, D.B. Rye, and B.H. Warner The origins of cholinergic and other subcortical afferents to the thalamus in the rat J Comp Neurol 262 1987 104 124
6. C.B. Saper, T.E. Scammell, and J. Lu Hypothalamic regulation of sleep and circadian rhythms Nature 437 2005 1257 1263 (Pubitemid 41568665)
7. B.E. Jones Arousal systems Front Biosci 8 2003 438 451
8. C.B. Saper Organization of cerebral cortical afferent systems in the rat. II. Hypothalamocortical projections J Comp Neurol 237 1985 21 46 (Pubitemid 15040605)
9. C.B. Saper, T.C. Chou, and T.E. Scammell The sleep switch: hypothalamic control of sleep and wakefulness Trends Neurosci 24 2001 726 731 (Pubitemid 33097540)
10. I. Gvilia Underlying brain mechanisms that regulate sleep-wakefulness cycles Int Rev Neurobiol 93 2010 1 21
11. E.M. Lo, I.V. Estabrooke, M. McCarthy, and T.E. Scammell Wake-related activity of tuberomammillary neurons in rats Brain Res 992 2003 220 226 (Pubitemid 37415104)
12. J. Lu, M.A. Greco, P. Shiromani, and C.B. Saper Effect of lesions of the ventrolateralpreoptic nucleus on NREM and REM sleep J Neurosci 20 2000 3830 3842 (Pubitemid 30266244)
13. M. Thakkar Histamine in the regulation of wakefulness Sleep Med Rev 15 (1) February 2011 65 74
14. C. Cianchetti, C. Masala, A. Mangoni, and G.L. Gessa Suppression of REM and delta sleep by apomorphine in man: a dopamine mimetic effect Psychopharmacology (Berl) 67 1980 61 65 (Pubitemid 10173721)
15. E. Galarraga, M. Corsi-Cabrera, and M. Sangri Reduction in paradoxical sleep after l-dopa administration in rats Behav Neural Biol 46 1986 249 256 (Pubitemid 17222837)
16. K. Svensson, P. Alfoldi, M. Hajos, G. Rubicsek, A.M. Johansson, and A. Carlsson Dopamine autoreceptor antagonists: effects on sleep-wake activity in the rat Pharmacol Biochem Behav 26 1987 123 129 (Pubitemid 18005614)
17. J. Lu, T.C. Jhou, and C.B. Saper Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter J Neurosci 26 (1) January 2006 193 202 (Pubitemid 43089532)
18. C. Idzikowski, F.J. Mills, and R. Glennard 5-Hydroxytryptamine-2- antagonist increases human slow wave sleep Brain Res 378 1986 164 168 (Pubitemid 16055814)
19. A.L. Sharpley, C.M. Vassalo, and P.J. Cowen Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo Biol Psychiatry 47 2000 468 470 (Pubitemid 30110618)
20. C. Dugovic, A. Wauquier, and P. Janssen Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat Neuropharmacology 28 1989 1431 1433 (Pubitemid 20008284)
21. N. Tsujino, and T. Sakurai Role of orexin in modulating arousal, feeding, and motivation Front Behav Neurosci 7 2013 28 10.3389/fnbeh.2013.00028 [eCollection 2013]
22. C. Iber, S. Ancoli-Israel, A.L. Chesson, and S.F. Quan The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications 1st ed. 2007 American Academy of Sleep Medicine Westchester, IL
23. J.B. Weilburg, J.W. Stakes, and T. Roth Sleep disorders T.A. Stern, J.F. Rosenbaum, M. Fava, J. Biederman, S.L. Rauch, Stern: massachusetts general hospital comprehensive clinical psychiatry 1st ed. 2008 Elsevier Health Sciences Boston 285 301 [Chapter 22]
24. American Psychiatric Association Diagnostic and statistical manual of mental disorder-text revision 4th ed. 2000 American Psychiatric Publishing Washington, DC
25. American Psychiatric Association Diagnostic and Statistical Manual of Mental disorder 5th ed 2013 American Psychiatric Publishing Washington, DC
26. K.L. Lichstein, N.M. Wilson, and C.T. Johnson Psychological treatment of secondary insomnia Psychol Aging 15 2000 232 240
27. S. Schutte-Rodin, L. Broch, D. Buysse, C. Dorsey, and M. Sateia Clinical guideline for the evaluation and management of chronic insomnia in adults J Clin Sleep Med 4 5 2008 487 504
28. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults June 13-15, 2005 Sleep 28 9 2005 1049 1057
29. 2002 Sleep in America Poll 2002 National Sleep Foundation Washington, DC
30. S. Gulyani, R.E. Salas, and C.E. Gamaldo Sleep medicine pharmacotherapeutics overview Chest 142 6 2012 1659 1668
31. American Academy of Sleep Medicine AASM Position Statement: Treating Insomnia with Over-the-Counter Sleep Aids, December 31 2006 http://www.aasmnet. org/Articles.aspx?id=253 [accessed 21.03.13].
32. A. Nunes, and M. Sousa Use of valerian in anxiety and sleep disorders: what is the best evidence? Acta Med Port 24 (Suppl. 4) December 2011 961 966
33. S. Bent, A. Padula, D. Morre, M. Patterson, and W. Mehling Valerian for sleep: a systematic review and meta-analysis Am J Med 119 2006 1005 1012 (Pubitemid 44826933)
34. D. Wheatly Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability J Psychopharmacol 19 2005 414 421
35. N. Buscemi, B. Vandermeer, R. Pandya, N. Hooton, L. Tjosvold, and L. Hartling Melatonin for treatment of sleep disorders Evid Rep Technol Assess (Summ) 108 2004 1 7
36. B. Guardiola-Lemaître Toxicology of melatonin J Biol Rhythms 12 6 1997 697 706
37. P. Foral, N. Dewan, and M. Malesker Insomnia: a therapeutic review for pharmacists Consult Pharm 26 (5) May 2011 332 341
38. J.K. Walsh, T.A. Roehrs, and T. Roth Pharmacologic treatment of primary insomnia M.H. Kryger, T. Roth, W.C. Dement, Principles and practice of sleep medicine 2005 Elsevier, Inc Philadelphia, PA 749 750
39. R.M. Benca Diagnosis and treatment of chronic insomnia: a review Psychiatr Serv 56 3 2005 332 343 (Pubitemid 40333567)
40. J.K. Walsh, and P.K. Schweitzer Ten-year trends in the pharmacological treatment of insomnia Sleep 22 1999 371 375 (Pubitemid 29230580)
41. G.W. Arana An overview of side effects caused by typical antipsychotics J Clin Psychiatry 61 Suppl. 8 2000 5 11
42. D.D. Miller Prim Care Companion J Clin Psychiatry 6 Suppl. 2 2004 3 7
43. R. Tandon Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 73 4 2002 297 311 (Pubitemid 38429494)
44. E. Richelson, and T. Souder Binding of antipsychotic drugs to human brain receptors: focus on newer generation antipsychotics Life Sci 68 2000 29 39
45. R.C. Hermann, D. Yang, S.L. Ettner, S.C. Marcus, C. Yoon, and M. Abraham Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997 Psychiatr Serv. 53 4 2002 425 430 Available at: http://ps.psychiatryonline.org/data/Journals/PSS/4346/425.pdf [accessed 18.03.13].
46. R.R. Aparasu, V. Bhatara, and S. Gupta U.S. national trends in the use of antipsychotics during office visits, 1998-2002 Ann Clin Psychiatry 17 3 2005 147 152 (Pubitemid 41176801)
47. R.R. Aparasu, E. Jano, and V. Bhatara Concomitant antipsychotic prescribing in US outpatient settings Res Social Adm Pharm 5 3 2009 234 241
48. D.L. Van Brunt, P.J. Gibson, J.L. Ramsey, and R. Obenchain Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000 MedGenMed 5 3 2003 16 Available at: http://www.medscape.com/ viewarticle/458984 [accessed 18.03.13].
49. J. Sankaranarayanan, and S.E. Puumala Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors Clin Ther 29 4 2007 723 741 (Pubitemid 47018273)
50. J. Sankaranarayanan, and S.E. Puumala Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004 Curr Med Res Opin 23 6 2007 1375 1385 (Pubitemid 46998446)
51. G.C. Alexander, S.A. Gallagher, A. Mascola, R.M. Moloney, and R.S. Stafford Increasing off-label use of antipsychotic medications in the United States, 1995-2008 Pharmacoepidemiol Drug Saf 20 2 2011 177 184 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069498/pdf/nihms-275845.pdf [accessed 25.03.13].
52. P.M. Haddad, and I.M. Anderson Antipsychotic-related QTc prolongation, torsades de pointes and sudden death Drugs 62 2002 1649 1671 (Pubitemid 34848372)
53. S. Wilson, and D. Nutt Management of insomnia: treatments and mechanisms Br J Psychiatry 191 2007 195 197 (Pubitemid 47435047)
54. C. Graziul, R. Gibbons, and G.C. Alexander Association between the commercial characteristics of psychotropic drugs and their off-label use Med Care 50 (11) November 2012 940 947
55. P. Kamble, J. Sherer, H. Chen, and R. Aparasu Off-label use of second-generation antipsychotic agents among elderly nursing home residents Psychiatr Serv 61 (2) February 2010 130 136
56. A. McKean, and E. Monasterio Off-label use of atypical antipsychotics: cause for concern? CNS Drugs 26 (5) May 2012 383 390
57. C. McCall, and W.V. McCall What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Curr Psychiatry Rep 14 2012 494 502
58. N. DeMartinis, and A. Winokur Effects of psychiatric medications on sleep and sleep disorders CNS Neurol Disord Drug Targets 6 1 2007 17 29 (Pubitemid 46322292)
59. S. Cohrs, A. Rodenbeck, Z. Guan, K. Pohlman, W. Jordan, and A. Meier Sleep-promoting properties of quetiapine in healthy subjects Psychopharmacology (Berl) 174 2004 421 429 (Pubitemid 39044301)
60. S. Cohrs, A. Meier, A.C. Neumann, W. Jordan, E. Ruther, and A. Rodenbeck Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects J Clin Psychiatry 66 2005 989 996 (Pubitemid 41191790)
61. M. Maglione, A. Ruelaz Maher, and J. Hu Off-label use of atypical antipsychotics: an update. Comparative effectiveness review no. 43 Prepared by the Southern California Evidence-Based Practice Center under Contract No. HHSA290-2007-10062-1 2011 Agency for Healthcare Research and Quality Rockville, MD
62. K. Tassniyom, S. Paholpak, S. Tassniyom, and J. Kiewyoo Quetiapine for primary insomnia: a double blind, randomized controlled trial J Med Assoc Thai 93 6 2010 729 734
63. E. Estivill, V. de la Fuente, F. Segarra, and J. Albares The use of olanzapine in sleep disorders. An open trial with nine patients Rev Neurol 38 (9) May 2004 829 831 (Pubitemid 38923971)
64. A.L. Sharpley, M.E. Attenburrow, S. Hafizi, and P.J. Cowen Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients J Clin Psychiatry 66 (4) April 2005 450 454 (Pubitemid 40593573)
65. C. Juri, P. Chaná, J. Tapia, C. Kunstmann, and T. Parrao Quetiapine for insomnia in Parkinson disease: results from an open-label trial Clin Neuropharmacol 28 (4) July-August 2005 185 187 (Pubitemid 41134246)
66. M. Pasquini, A. Speca, and M. Biondi Quetiapine for tamoxifen-induced insomnia in women with breast cancer Psychosomatics 50 2 2009 159 161
67. A. Teran, S. Majadas, and J. Galan Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study Subst Use Misuse 43 14 2008 2169 2171
68. M.H. Wiegand, F. Landry, T. Bruckner, C. Pohl, Z. Veselý, and T. Jahn Quetiapine in primary insomnia: a pilot study Psychopharmacology (Berl) 196 2 2008 337 338
69. C.R. Dolder, and J. McKinsey Quetiapine for sleep in patients with dementia Consult Pharm 25 10 2004 676 679
70. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, and M.C. Infante Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1999 1686 1696 (Pubitemid 29517559)
71. D.M. Gardner, R.J. Baldessarini, and P. Waraich Modern antipsychotic drugs: a critical overview Can Med Assoc J 172 13 2005 1703 1711 (Pubitemid 40896865)
72. J.A. Lieberman, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, and D.O. Perkins Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 (12) September 2005 1209 1223 (Pubitemid 41345943)
73. L.S. Schneider, M.S. Ismail, K. Dagerman, S. Davis, J. Olin, and D. McManus Clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial Schizophr Bull 29 1 2003 57 72 (Pubitemid 36871057)
74. E.A. Koller, J. Weber, P.M. Doraiswamy, and B.S. Schneider A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus J Clin Psychiatry 65 6 2004 857 863
75. E.A. Koller, J.T. Cross, and B. Schneider Risperidone-associated diabetes mellitus in children Pediatrics 113 2 2004 421 422 [author reply 421-2]
76. E. Koller, S. Malozowski, and P.M. Doraiswamy Atypical antipsychotic drugs and hyperglycemia in adolescents JAMA 286 20 2001 2547 2548 (Pubitemid 33096804)
77. C.E. Koro, D.O. Fedder, G.J. L'Italien, S. Weiss, L.S. Magder, and J. Kreyenbuhl An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients Arch Gen Psychiatry 59 2002 1021 1026
78. C.E. Koro, D.O. Fedder, G.J. L'Italien, S.S. Weiss, L.S. Magder, and J. Kreyenbuhl Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case control study BMJ 325 2002 243 247
79. Pfizer Inc FDA Psychopharmacological Drugs Advisory Committee Briefing document for Zeldox capsules (ziprasidoneHCl) 2000 Pfizer Inc. Available at: www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf [accessed 18.03.13]
80. E.H. Morrato, J.W. Newcomer, S. Kamat, O. Baser, J. Harnett, and B. Cuffel Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes Diabetes Care 32 6 2009 1037 1042
81. D.W. Haupt, L.C. Rosenblatt, E. Kim, R.A. Baker, R. Whitehead, and J.W. Newcomer Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents Am J Psychiatry 166 3 2009 345 353
82. J. Hennen, R.H. Perlis, G. Sachs, M. Tohen, and R.J. Baldessarini Weight gain during treatment of bipolar I patients with olanzapine J Clin Psychiatry 65 2004 1679 1687
83. FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients 2005 US Food and Drug Administration Rockville, MD [FDA Talk Paper]
84. Olanzapine (marketed as Zyprexa): increased mortality in patients with dementia-related psychosis 2005 US Food and Drug Administration Rockville, MD [FDA Alert 04.11.05]
85. P. Shekelle, M. Maglione, and S. Bagley Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Comparative effectiveness review no. 6 Prepared by the Southern California Evidence-Based Practice Center under Contract No. HHSA290-2007-10062-1 2007 Agency for Healthcare Research and Quality Rockville, MD
86. C.A. Yury, and J.E. Fisher Meta-analysis of the effectiveness of SGAs for the treatment of behavioural problems in persons with dementia Psychother Psychosom 76 4 2007 213 218 (Pubitemid 46933366)
87. C.U. Correll, S. Leucht, and J.M. Kane Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies Am J Psychiatry 161 3 2004 414 425 (Pubitemid 38326094)
88. C.M. Beasley, M.A. Dellva, R.N. Tamura, H. Morgenstern, W.M. Glazer, and K. Ferguson Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol Br J Psychiatry 174 1999 23 30 (Pubitemid 29037880)
89. C.L. Vigen, W.J. Mack, R.S. Keefe, M. Sano, D.L. Sultzer, and T.S. Stroup Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's Disease: outcomes from CATIE-AD Am J Psychiatry 168 8 2011 831 839
90. D.T. Chen, M.K. Wynia, R.M. Moloney, and G.C. Alexander U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey Pharmacoepidemiol Drug Saf 18 (11) November 2009 1094 1100
91. R.C. Rosen, M. Rosekind, C. Rosevear, W.E. Cole, and W.C. Dement Physician education in sleep and sleep disorders: a national survey of US medical schools Sleep 16 1993 249 254 (Pubitemid 23119049)
92. K.K. Papp, C.E. Penrod, and K.P. Strohl Knowledge and attitudes of primary care physicians toward sleep and sleep disorders Sleep Breath 6 2002 103 109
93. H.V. Coe, and I.S. Hong Safety of low doses of quetiapine when used for insomnia Ann Pharmacother 46 (5) May 2012 718 722
94. S. Zhornitsky, S. Potvin, H. Moteshafi, S. Dubreucq, P.P. Rompré, and E. Stip Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials Int Clin Psychopharmacol 26 (4) July 2011 183 192